Zevaquenabant

立即咨询

Zevaquenabant

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1998760-00-1

(S)-MRI-1867

Zevaquenabant ((S)-MRI-1867) 是一种受外周限制的，具有口服生物利用的大麻素CB1受体和诱导型 NOS(iNOS)双拮抗剂。Zevaquenabant 改善肥胖引起的慢性肾脏疾病 (CKD)。

生物活性

Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoidCB1receptorand inducible NOS(iNOS)antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)^[1].

IC₅₀& Target^[1]

CB1

iNOS

体外研究
(In Vitro)

Zevaquenabant can simultaneously inhibit CB1 receptors and iNOS in peripheral organs^[1].

体内研究
(In Vivo)

Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice^[1].

Animal Model:	6-week-old male C57Bl/6J mice (diet-induced obesity)^[1]
Dosage:	3 mg/kg
Administration:	P.o.; for 28 days
Result:	Improved kidney morphology and function in diet-induced obese mice.

分子量

547.98

Formula

C₂₅H₂₁ClF₃N₅O₂S

CAS 号

1998760-00-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.